Online inquiry

IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5383MR)

This product GTTS-WQ5383MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets env gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Pseudomonas aeruginosa; Homo sapiens
RefSeq NP_579894.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 155971
UniProt ID P04578
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5383MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7433MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ12582MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ3910MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ1254MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ9618MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ11943MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ14452MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ975MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW